成人2型糖尿病患者口服降糖药物三联优化方案(二甲双胍+二肽基肽酶4抑制剂+ 钠⁃葡萄糖共转运蛋白2抑制剂)中国专家共识

2021-08-20 中国研究型医院学会 中国糖尿病杂志

随着新型口服降糖药(OAD)二肽基肽酶4抑制剂(DPP⁃4i)、钠⁃葡萄糖共转运蛋白2 抑制剂(SGLT2i)上世后循证证据的积累,为治疗T2DM提供了新选择,也促进了降糖方案不断优化。

中文标题:

成人2型糖尿病患者口服降糖药物三联优化方案(二甲双胍+二肽基肽酶4抑制剂+ 钠⁃葡萄糖共转运蛋白2抑制剂)中国专家共识

发布机构:

中国研究型医院学会

发布日期:

2021-08-20

简要介绍:

随着新型口服降糖药(OAD)二肽基肽酶4抑制剂(DPP⁃4i)、钠⁃葡萄糖共转运蛋白2 抑制剂(SGLT2i)上世后循证证据的积累,为治疗T2DM提供了新选择,也促进了降糖方案不断优化。为提高临床医生对Met+DPP⁃4i+SGLT2i 三联优化方案的认识,规范其临床应用,中国研究型医院学会糖尿病学专业委员会组织有关专家,根据循证医学证据和临床实践经验,经多次讨论修改制定本专家共识,以推荐在无酮症、血清转氨酶≤3×正常值上限(ULN)及eGFR≥45 ml/(min·1. 73 m2)的成人T2DM 患者治疗中参考。

相关资料下载:
[AttachmentFileName(sort=1, fileName=成人2型糖尿病患者口服降糖药物三联优化方案中国专家共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=896a41c002213387, title=成人2型糖尿病患者口服降糖药物三联优化方案(二甲双胍+二肽基肽酶4抑制剂+ 钠⁃葡萄糖共转运蛋白2抑制剂)中国专家共识, enTitle=, guiderFrom=中国糖尿病杂志, authorId=0, author=, summary=随着新型口服降糖药(OAD)二肽基肽酶4抑制剂(DPP⁃4i)、钠⁃葡萄糖共转运蛋白2 抑制剂(SGLT2i)上世后循证证据的积累,为治疗T2DM提供了新选择,也促进了降糖方案不断优化。, cover=https://img.medsci.cn/20211018/1634560997785_5579292.jpg, journalId=0, articlesId=null, associationId=1023, associationName=中国研究型医院学会, associationIntro=中国研究型医院学会,英文名称Chinese Research Hospital Association(CRHA),是经国家民政部正式批复并登记注册的全国性一级学会,是独立的法人社团。中国研究型医院学会是由以探索和建设研究型医院为目标的具有医疗服务、科学研究和临床教学&ldquo;三位一体&rdquo;功能的医疗机构,以及从事研究型医院理论与实践研究的人员自愿结成的全国性、专业性、学术性、非营利性社会组织。, copyright=0, guiderPublishedTime=Fri Aug 20 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">随着新型口服降糖药(OAD)二肽基肽酶4</span><span style="color: #373737;">抑制剂(DPP⁃4i)、钠⁃葡萄糖共转运蛋白2 抑制剂</span><span style="color: #373737;">(SGLT2i)上世后循证证据的积累,为治疗T2DM</span><span style="color: #373737;">提供了新选择,也促进了降糖方案不断优化。</span><span style="color: #373737;">为提高临床医生对Met+DPP⁃4i+SGLT2i 三</span><span style="color: #373737;">联优化方案的认识,规范其临床应用,中国研究型</span><span style="color: #373737;">医院学会糖尿病学专业委员会组织有关专家,根</span><span style="color: #373737;">据循证医学证据和临床实践经验,经多次讨论修</span><span style="color: #373737;">改制定本专家共识,以推荐在无酮症、血清转氨酶</span><span style="color: #373737;">&le;3&times;正常值上限(ULN)及eGFR&ge;45 ml/(min&middot;</span><span style="color: #373737;">1. 73 m<sup>2</sup>)的成人T2DM 患者治疗中参考。</span></p>, tagList=[TagDto(tagId=100585, tagName=成人2型糖尿病)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=8, categoryName=糖尿病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=100585, guiderKeyword=成人2型糖尿病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=108962, appHits=233, showAppHits=0, pcHits=1734, showPcHits=108729, likes=2, shares=30, comments=11, approvalStatus=1, publishedTime=Mon Oct 18 21:05:33 CST 2021, publishedTimeString=2021-08-20, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Mon Oct 18 20:46:38 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 15:34:40 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=成人2型糖尿病患者口服降糖药物三联优化方案中国专家共识.pdf)])
成人2型糖尿病患者口服降糖药物三联优化方案中国专家共识.pdf
下载请点击:
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1217056, encodeId=09a9121e0565b, content=学习~, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46445576118, createdName=枫语Lily, createdTime=Thu May 05 14:27:16 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198042, encodeId=7d10119804284, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d585243593, createdName=光明骑士, createdTime=Mon Feb 28 15:24:17 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179816, encodeId=fc7f11e98165e, content=进来学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10b5724805, createdName=ms9000001018126212, createdTime=Sun Jan 02 17:06:11 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080622, encodeId=6573108062205, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:47:13 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074597, encodeId=e37d10e45978b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14335617962, createdName=ms8000001755238620, createdTime=Sat Nov 27 20:17:46 CST 2021, time=2021-11-27, status=1, ipAttribution=)]
    2022-05-05 枫语Lily

    学习~

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1217056, encodeId=09a9121e0565b, content=学习~, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46445576118, createdName=枫语Lily, createdTime=Thu May 05 14:27:16 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198042, encodeId=7d10119804284, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d585243593, createdName=光明骑士, createdTime=Mon Feb 28 15:24:17 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179816, encodeId=fc7f11e98165e, content=进来学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10b5724805, createdName=ms9000001018126212, createdTime=Sun Jan 02 17:06:11 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080622, encodeId=6573108062205, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:47:13 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074597, encodeId=e37d10e45978b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14335617962, createdName=ms8000001755238620, createdTime=Sat Nov 27 20:17:46 CST 2021, time=2021-11-27, status=1, ipAttribution=)]
    2022-02-28 光明骑士

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1217056, encodeId=09a9121e0565b, content=学习~, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46445576118, createdName=枫语Lily, createdTime=Thu May 05 14:27:16 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198042, encodeId=7d10119804284, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d585243593, createdName=光明骑士, createdTime=Mon Feb 28 15:24:17 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179816, encodeId=fc7f11e98165e, content=进来学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10b5724805, createdName=ms9000001018126212, createdTime=Sun Jan 02 17:06:11 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080622, encodeId=6573108062205, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:47:13 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074597, encodeId=e37d10e45978b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14335617962, createdName=ms8000001755238620, createdTime=Sat Nov 27 20:17:46 CST 2021, time=2021-11-27, status=1, ipAttribution=)]
    2022-01-02 ms9000001018126212

    进来学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1217056, encodeId=09a9121e0565b, content=学习~, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46445576118, createdName=枫语Lily, createdTime=Thu May 05 14:27:16 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198042, encodeId=7d10119804284, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d585243593, createdName=光明骑士, createdTime=Mon Feb 28 15:24:17 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179816, encodeId=fc7f11e98165e, content=进来学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10b5724805, createdName=ms9000001018126212, createdTime=Sun Jan 02 17:06:11 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080622, encodeId=6573108062205, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:47:13 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074597, encodeId=e37d10e45978b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14335617962, createdName=ms8000001755238620, createdTime=Sat Nov 27 20:17:46 CST 2021, time=2021-11-27, status=1, ipAttribution=)]
    2021-12-16 龙珠

    学习好资料

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1217056, encodeId=09a9121e0565b, content=学习~, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46445576118, createdName=枫语Lily, createdTime=Thu May 05 14:27:16 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198042, encodeId=7d10119804284, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d585243593, createdName=光明骑士, createdTime=Mon Feb 28 15:24:17 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179816, encodeId=fc7f11e98165e, content=进来学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10b5724805, createdName=ms9000001018126212, createdTime=Sun Jan 02 17:06:11 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080622, encodeId=6573108062205, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:47:13 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074597, encodeId=e37d10e45978b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14335617962, createdName=ms8000001755238620, createdTime=Sat Nov 27 20:17:46 CST 2021, time=2021-11-27, status=1, ipAttribution=)]
    2021-11-27 ms8000001755238620

    0

拓展阅读

2022 AHA科学声明:成人2型糖尿病心血管危险因素综合管理

美国心脏协会(AHA,American Heart Association) · 2022-01-10

2022更新—2015 NICE指南:成人2型糖尿病的管理(NG.28)

英国国家卫生与临床优化研究所 (NICE,National Institute for Health and Clinical Excellence) · 2022-03-31

关于公开征求《成人2型糖尿病药物临床研发技术指导原则》意见的通知

国家药品监督管理局药品审评中心(CDE) · 2022-06-27

2022 NICE 指南:成人 2 型糖尿病:管理[NG28](最近更新时间: 2022 年 6 月 29 日)

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2022-06-29

【中文译文】2022更新—2015 NICE指南:成人2型糖尿病的管理(NG.28)

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2022-03-31